Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Memory Problems Clinical Trials

A listing of Memory Problems medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in ...

Phase

The purpose of this study is to evaluate Donepezil and Memantine for the treatment of Alzheimer's disease.

Phase

SPRI Clinical Trials of Brooklyn, under the sponsorship of Suven Life Sciences, is currently participating in the clinical evaluation of the safety and effectiveness of an investigational drug in persons with moderate dementia due to Alzheimer’s disease.

Phase

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day in the treatment of subjects with mild Alzheimer's Disease compared to placebo.

Phase

This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem™ once daily in adult subjects with mild dementia due to AD.

Phase

Study Description: The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype. ...

Phase

Multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg and 90 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.  

Phase